Impact of comprehensive treatment for first episode psychosis on substance use outcomes: A randomized controlled trial

Corinne Cather, Mary F. Brunette, Kim T. Mueser, Steven F. Babbin, Robert Rosenheck, Christoph U. Correll, Piper Kalos-Meyer

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Lifetime co-occurring substance use disorders are common at the time of presentation for treatment of a first episode of primary psychosis and persistent substance use disorder (SUD) leads to poorer outcomes. We assessed whether the NAVIGATE program, a coordinated specialty care service that includes optional substance abuse content reduced substance use compared to usual care in 404 individuals in the Recovery After Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) study. Participants were randomized to two years of NAVIGATE (n = 223) or usual care (n = 181) and assessed monthly for substance use. At baseline, over one-half (51.7%) of the participants met criteria for a lifetime SUD, including over one-third with alcohol use disorder (36.4%) and with cannabis use disorder (34.7%). Contrary to our hypothesis, there was no treatment group by time interaction effect on days of self-reported substance use over the two-year follow-up. Participant exposure to the substance abuse component of the NAVIGATE program was low, suggesting that modifications to the program and training method for clinicians may be needed. Further research is needed to determine the most effective strategies for addressing substance use disorders in persons recovering from a first episode of psychosis.

Original languageEnglish (US)
Pages (from-to)303-311
Number of pages9
JournalPsychiatry Research
Volume268
DOIs
StatePublished - Oct 2018

Bibliographical note

Funding Information:
Dr. Correll has been a consultant or adviser to or has received honoraria from Alkermes, Bristol-Myers Squibb, Gerson Lehrman Group, Intra-Cellular Therapies, Janssen, Johnson and Johnson, LB Pharma, Lundbeck, MedAvante, Medscape, Neurocrine, Otsuka, Pfizer, ProPhase, ROVI, Sunovion, Takeda and Teva; and he has received grant support from Janssen and Takeda. He has provided expert testimony for Bristol-Meyers Squibb and Otsuka. He is a share holder of LB Pharma.

Funding Information:
This work has been funded in whole or in part with funds from the American Recovery and Reinvestment Act and from NIMH under contract HHSN271200900019

Publisher Copyright:
© 2018

Keywords

  • Alcohol
  • Cannabis
  • Psychosocial research
  • Recovery after an initial psychotic episode (raise)
  • Schizophrenia
  • Treatment outcomes

Fingerprint

Dive into the research topics of 'Impact of comprehensive treatment for first episode psychosis on substance use outcomes: A randomized controlled trial'. Together they form a unique fingerprint.

Cite this